Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Homoharringtonine × 1 year × Clear all

Phase

Phase 2 3 Phase 1/2 2 Phase 3 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1 Hematologic Neoplasms 1

Interventions

pembrolizumab 223 Cyclophosphamide 222 Specimen Handling 176 fludarabine 156 Magnetic Resonance Spectroscopy 153 Biopsy 132 Nivolumab 120 Carboplatin 94 Radiotherapy 86 Paclitaxel 81 Gemcitabine 77 venetoclax 76 fludarabine phosphate 75 Cisplatin 75 Injections 64 Bevacizumab 59 Ipilimumab 56 atezolizumab 55 Dexamethasone 55 Azacitidine 55 Radiation 54 Fluorouracil 53 Radiosurgery 51 durvalumab 50 Cetuximab 49 Temozolomide 47 Docetaxel 47 Oxaliplatin 42 Rituximab 41 Irinotecan 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡